Linezolid vancomycin resistant Enterococcus isolated from clinical samples in Tehran hospitals

Vancomycin-resistant enterococci pose an emerging health risk. The limitation in therapeutic options has resulted in the development of new drugs such as quinupristin/ dalfopristin and linezolid. AIM, SETTING AND DESIGN: This study investigated the species prevalence and antibacterial resistance amo...

Full description

Saved in:
Bibliographic Details
Published inIndian journal of medical sciences Vol. 63; no. 7; p. 297
Main Authors Yasliani, S, Mohabati Mobarez, A, Hosseini Doust, R, Satari, M, Teymornejad, O
Format Journal Article
LanguageEnglish
Published India 01.07.2009
Subjects
Acetamides - pharmacology
Anti-Infective Agents - pharmacology
Drug Resistance, Multiple, Bacterial - genetics
Enterococcus - drug effects
Enterococcus - genetics
Enterococcus - isolation & purification
Gram-Positive Bacterial Infections - drug therapy
Gram-Positive Bacterial Infections - epidemiology
Gram-Positive Bacterial Infections - microbiology
Hospitals, Teaching
Humans
Iran - epidemiology
Linezolid
Microbial Sensitivity Tests
Oxazolidinones - pharmacology
Prevalence
Serum Bactericidal Test
Teicoplanin - pharmacology
Vancomycin Resistance - genetics
Iran
Online AccessGet more information

Cover

More Information
Summary:Vancomycin-resistant enterococci pose an emerging health risk. The limitation in therapeutic options has resulted in the development of new drugs such as quinupristin/ dalfopristin and linezolid. AIM, SETTING AND DESIGN: This study investigated the species prevalence and antibacterial resistance among enterococci isolated in selected Tehran hospitals. Between March 2006 and August 2007, 200 enterococcal isolates from urine, blood, stool and wound were recovered in 2 teaching hospitals of Tehran province. Susceptibility of all isolates was tested against vancomycin, teicoplanin and linezolid antibiotics by disk diffusion and agar dilution method. Seventeen (8.5%), 6 (3%) and 4 (2%) of the isolates were resistant to vancomycin, teicoplanin and linezolid, respectively. Within the vancomycin-resistant isolates, 6 (35.2%), 4 (25%) and 1 (5.88%) showed vanA, vanB and vanC genotype patterns, respectively. Four (23.5%) of VRE isolates were resistant to linezolid with minimum inhibitory concentrations between 16 and 32 microg/mL. Two linezolid vancomycin resistant enterococci were E. faecium.
ISSN:1998-3654